MAP — Microba Life Sciences Cashflow Statement
0.000.00%
- AU$73.90m
- AU$47.22m
- AU$5.42m
- 14
- 23
- 46
- 16
Annual cashflow statement for Microba Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | R2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.068 | 0.458 | 1.16 | 2.85 | 3.53 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -3.62 | -4.32 | -7.18 | -10.4 | -12.4 |
Capital Expenditures | -0.836 | -0.856 | -0.672 | -1.87 | -3.04 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.002 | 0 | 0.1 | 0.14 | 0.038 |
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.834 | -0.856 | -0.573 | -1.73 | -3 |
Financing Cash Flow Items | 3.24 | 0.014 | -0.951 | -1.9 | -0.596 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 13.7 | 1.08 | 13.8 | 29.2 | 16.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 9.26 | -4.1 | 6.08 | 17.6 | 1.46 |